AlphAIAlphAI — Financial news for AI agents
prnewswire.comAUG 37 min read$CGEN

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

Original reporting
prnewswire.com
Published Aug 3, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CGEN
Bullish
medium confidence
Mentioned
$CGEN
Relevance
7/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$CGENBullishMed
01

Why it matters

This release combines (1) Q2 2026 financial updates, (2) a reiterated clinical catalyst timeline for COM701 in platinum-sensitive ovarian cancer, and (3) partner program progress and a new overall survival readout for AstraZeneca’s rilvegostomig in biliary tract cancer.

02

Market read

Traders can use the reiterated COM701 interim-analysis timing (Q1 2027) and the stated cash runway into 2029 to frame biotech risk, while the new partner OS readout for rilvegostomig adds sentiment support for the broader checkpoint-pathway theme.

03

What to watch

Cash runway into 2029 is supportive, but the article does not quantify trial enrollment progress, event counts, or probability of success for COM701, which are key drivers of valuation for pre-registration-stage assets.

Relevance 7/10Novelty 6/10Timing: today’s Aug 3 pre-market/market open context ahead of the company’s 8:30 AM ET call

Background

Compugen is a clinical-stage cancer immunotherapy company with an AI/ML discovery platform (Unigen) and partnered programs including AstraZeneca’s rilvegostomig and Gilead’s GS-0321.

Company-level read

Ticker impact

$CGENBullishMedium confidence
Context

Compugen reported Q2 2026 results and said its MAIA-ovarian COM701 interim analysis with median PFS is expected by Q1 2027.

Expected impact

Moderate positive bias, with volatility likely into the next clinical milestone and any follow-on partner updates.

Evidence & confidence

The article provides fresh company-specific disclosures: Q2 financials, cash runway guidance, and a reiterated timing for the COM701 interim analysis. However, it does not include a new efficacy datapoint or regulatory decision that would typically drive a large immediate repricing.

Market effects

Sector

Reinforces investor attention on checkpoint-pathway innovation beyond PD-1/TIGIT (PVRIG) and on platform trial readouts as catalysts for oncology immunotherapy developers.

Regional

Limited direct regional spillover; primarily impacts US-listed biotech sentiment.

Global

Partnered late-stage oncology programs (AstraZeneca) and IL-18 pathway interest (Gilead-linked GS-0321) may marginally influence global biotech risk sentiment.

Counterpoint

What could challenge this read

The reiterated Q1 2027 interim-analysis timing is not a new clinical result, so the market may already be pricing the catalyst; near-term reaction could fade if investors want hard efficacy updates sooner.

Key entities

  • company
    Compugen Ltd.

    Subject of the earnings and corporate update, including COM701 MAIA-ovarian interim-analysis timing and Q2 2026 financial highlights.

  • clinical_program
    COM701

    Compugen’s anti-PVRIG antibody in the MAIA-ovarian adaptive platform trial; interim median PFS expected by Q1 2027.

  • partner
    AstraZeneca

    Partner presenting rilvegostomig data at ASCO 2026 and initiating an additional Phase 3 trial.

  • clinical_program
    rilvegostomig

    PD-1/TIGIT bispecific antibody; ASCO 2026 first overall survival readout reported with median OS 16.8 months.

  • partner
    Gilead

    Partner for GS-0321, with the Phase 1 dose-escalation trial progressing as planned.

Read at source← All news

Related articles

OCT 8
$VODMed

Vodafone seeks to cut UK costs by £1 billion by 2032

Vodafone aims to save £1 billion annually in UK costs by 2032, raising its target from £800 million. The company expects mid-to-high single-digit EBITDAaL growth and a threefold increase in operating free cash flow by 2032. CEO Margherita Della Valle cited confidence in the upgraded target.

finance.yahoo.com2 min
OCT 8
$LEVIHighAI 9/10

Levi Strauss Lifts Profit Guidance, but Tariff Refund Flatters the Beat

Levi Strauss (LEVI) raised its full-year profit guidance after Q3 adjusted earnings of $0.48 per share beat estimates, though revenue of $1.6B met expectations. The beat was partly due to a $79M tariff refund. Shares closed at $19.51, down 4.97% pre-earnings. The company plans to redeploy $60M into direct-to-consumer initiatives, which make up 45% of revenue. Guidance for gross margin and revenue growth was also adjusted.

asktraders.com2 min
OCT 8
$005930.KSMedAI 8/10

Record profits fail to impress Samsung investors

Samsung Electronics reported a record quarterly operating profit of 107.4 trillion won, up 782.5% year-over-year. Despite this, shares fell 2.42% as investors questioned the sustainability of earnings growth. Analysts are divided on the outlook, with some predicting a prolonged memory chip upcycle and others cautioning of a potential downturn. The company plans to return 50% of its free cash flow to shareholders between 2024 and 2026.

koreatimes.co.kr3 min
OCT 8
$WSMedAI 8/10

Worthington Steel Inc (WS) (Q1 2027) Earnings Call Highlights: Kloeckner Acquisition Drives

Worthington Steel Inc (WS) reported Q1 2027 earnings with $954M net sales, up 9% YoY, and adjusted EBITDA of $111M. The Kloeckner acquisition expanded operations but resulted in a net loss of $7M due to higher interest and purchase accounting impacts. Automotive and agriculture shipments grew, while energy and construction declined. Net debt stands at $1.9B. Management expects synergy benefits post-integration.

finance.yahoo.com3 min
OCT 8
$005930.KSMedAI 8/10

Foreign selling and ETF rebalancing drag South Korea stocks despite Samsung beat

South Korea's KOSPI index fell 2.62% to 6,625.93 despite Samsung Electronics(005930) reporting record earnings of 10.74 trillion won. Foreign and institutional selling, ETF rebalancing, and profit-taking drove the decline. Samsung's stock dropped 2.42%, while LG Energy Solution(373220) and Samsung SDI gained. Other major stocks like SK hynix(000660) and Hyundai Motor also fell.

biz.chosun.com2 min
OCT 8
$005930.KSHighAI 9/10

Samsung becomes first tech giant to top W100tr quarterly profit

Samsung Electronics reported a record quarterly operating profit of 107.4 trillion won, up 782.5% year-over-year, driven by strong demand for memory chips. Revenue also hit a record 195 trillion won. Despite this, shares fell 1.77% amid broader market declines. Analysts estimate memory business profits offset losses in other divisions. The company plans to expand production and offer employee bonuses in shares.

theinvestor.co.kr2 min